Mercado de vectores lentivirales en Asia y el Pacífico: tendencias de la industria y pronóstico hasta 2028

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de vectores lentivirales en Asia y el Pacífico: tendencias de la industria y pronóstico hasta 2028

  • Healthcare
  • Published Report
  • Jun 2021
  • Asia-Pacific
  • 350 Páginas
  • Número de tablas: 212
  • Número de figuras: 52

>Mercado de vectores lentivirales de Asia-Pacífico, por componente (promotor lentiviral, etiquetas de fusión lentiviral, sistemas de empaquetado lentiviral, otros), tipo (producto, servicios), generación (cuarta generación, tercera generación, segunda generación, primera generación), flujo de trabajo (procesamiento ascendente, procesamiento descendente), método de administración (in vivo, ex vivo), indicación de enfermedad (cáncer, trastornos genéticos, enfermedades infecciosas , enfermedades veterinarias, otras), aplicación (terapia génica, vaccinología), usuario final (empresas de biotecnología, empresas farmacéuticas, organizaciones de investigación por contrato, organización de desarrollo y fabricación por contrato (CDMO), institutos académicos/de investigación), país (Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, resto de Asia-Pacífico) Tendencias de la industria y pronóstico hasta 2028

Mercado de vectores lentivirales en Asia y el Pacífico

Análisis y perspectivas del mercado : mercado de vectores lentivirales en Asia y el Pacífico

Se espera que el mercado de vectores lentivirales gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 16,1% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 207,37 millones para 2028. La creciente demanda de vectores lentivirales y el aumento de las enfermedades infecciosas son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.

Los vectores lentivirales (LV) son vehículos eficientes para la transferencia de genes en células de mamíferos debido a su capacidad de expresar de manera estable un gen de interés en células que no se dividen y en células que se dividen. Los lentivirus son patógenos humanos y animales que se sabe que tienen largos períodos de incubación e infección persistente. El tiempo entre la infección inicial y la aparición de los primeros síntomas puede alcanzar varios meses o años.

Los biólogos moleculares utilizan con frecuencia vectores virales para introducir material genético en las células. Este procedimiento puede llevarse a cabo in vivo (dentro de un organismo vivo) o en un cultivo celular (in vitro). Los virus han desarrollado mecanismos moleculares especializados para transportar sus genomas de manera eficiente dentro de las células que infectan.

El aumento de la población geriátrica y la demanda de desarrollos de vacunas durante la emergencia de Covid-19 ayudan de manera efectiva al crecimiento del mercado de vectores lentivirales. Sin embargo, la falta de escalabilidad y las limitaciones de la purificación posterior de los vectores lentivirales pueden obstaculizar el crecimiento futuro de un mercado de vectores lentivirales. Las iniciativas estratégicas de los principales actores del mercado y el aumento de la financiación para la genómica actúan como una oportunidad para el crecimiento del mercado de vectores lentivirales en Asia y el Pacífico. Las estrictas políticas regulatorias y los efectos secundarios asociados con los productos de vectores lentivirales actúan como un desafío para el crecimiento futuro del mercado.

El informe de mercado de vectores lentivirales proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsas de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado de vectores lentivirales en Asia y el Pacífico

Alcance y tamaño del mercado de vectores lentivirales en Asia y el Pacífico

El mercado de vectores lentivirales está segmentado en ocho segmentos notables que se basan en el componente, el tipo, la generación, el flujo de trabajo, el método de administración, la indicación de la enfermedad, la aplicación y el usuario final. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

  • En función de los componentes, el mercado de vectores lentivirales se segmenta en promotores lentivirales, etiquetas de fusión lentivirales, sistemas de empaquetado de lentivirus y otros. En 2021, se espera que el segmento de sistemas de empaquetado de lentivirus domine el mercado de vectores lentivirales debido al aumento de los avances en la investigación en China, Japón y otros países de Asia-Pacífico.
  • Según el tipo, el mercado de vectores lentivirales se segmenta en productos y servicios. En 2021, se espera que el segmento de productos domine el mercado de vectores lentivirales debido a la alta población geriátrica.
  • En función de la generación, el mercado de vectores lentivirales se segmenta en cuarta generación, tercera generación, segunda generación y primera generación. En 2021, se espera que el segmento de cuarta generación domine el mercado de vectores lentivirales debido a sus menores efectos secundarios asociados con las aplicaciones de terapia génica.
  • En función del flujo de trabajo, el mercado de vectores lentivirales se segmenta en procesamiento ascendente y procesamiento descendente. En 2021, se espera que el segmento de procesamiento ascendente domine el mercado de vectores lentivirales debido al aumento de la mano de obra calificada en institutos de investigación y empresas farmacéuticas.
  • Según el método de administración, el mercado de vectores lentivirales se segmenta en in vivo y ex vivo. En 2021, se espera que el segmento in vivo domine el mercado de vectores lentivirales debido al creciente desarrollo de ensayos clínicos para vectores virales.
  • En función de la indicación de la enfermedad, el mercado de vectores lentivirales se segmenta en cáncer, trastornos genéticos, enfermedades infecciosas, enfermedades veterinarias y otras. En 2021, se espera que el segmento del cáncer domine el mercado de vectores lentivirales debido a la alta población y prevalencia de casos de cáncer.
  • En función de la aplicación, el mercado de vectores lentivirales se segmenta en terapia génica y vaccinología. En 2021, se espera que el segmento de la terapia génica domine el mercado de vectores lentivirales debido a la amplia difusión del turismo médico en los países asiáticos.
  • On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government fund for research and development procedures.

Lentiviral Vector Market Country Level Analysis

The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.

The countries covered in the lentiviral vector market report in this region are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.

Products segment is dominating in China which is leading in the Asia-Pacific region due to high geriatric population and high vaccine production.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market 

Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.  

Competitive Landscape and Lentiviral Vector Market Share Analysis

Lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.

Las principales empresas que se dedican al vector lentiviral son Merck KGaA, FinVector Oy, Oxford Biomedica, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, Batavia Biosciences BV, Waisman Biomanufacturing, Cytiva (una subsidiaria de Danaher), bluebird bio, Inc., System Biosciences, LLC, COBRA BIOLOGICS, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Cell Biolabs, Inc., Lonza, GENEMEDI y FUJIFILM Diosynth Biotechnologies (una subsidiaria de FUJIFILM Holdings Corporation), entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.

Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de vectores lentivirales.

Por ejemplo,

  • En febrero de 2021, Thermo Fisher Scientific Inc. anunció que había ganado seis premios en los premios anuales CMO Leadership Awards. Los premios, otorgados por Life Science Leader y Outsourced Pharma, reconocen a los principales socios de fabricación por contrato según la evaluación de las empresas biofarmacéuticas y biotecnológicas. Se estima que este reconocimiento fortalecerá su presencia a nivel mundial y conducirá a un repunte de su crecimiento en los próximos años.

La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la presencia de la empresa en el mercado de vectores lentivirales, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.

 

 


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 COMPONENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW

4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE

4.2.1 PRODUCT

4.2.2 SERVICES

5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK

5.1 REGULATION IN THE UNITED STATES

5.2 REGULATIONS IN EUROPE

5.3 REGULATIONS IN INDIA

5.4 REGULATIONS IN JAPAN

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN DEMAND FOR VIRAL VECTORS

6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT

6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY

6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES

6.1.5 GROWING GERIATRIC POPULATION

6.2 RESTRAINTS

6.2.1 LACK OF SCALABILITY

6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION

6.2.3 SHORTAGE OF SKILLED PERSONNELS

6.3 OPPORTUNITIES

6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS

6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT

6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES

6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES

6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION

7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

7.5 CONCLUSION

8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT

8.1 OVERVIEW

8.2 LENTIVIRUS PACKAGING SYSTEMS

8.3 LENTIVIRAL PROMOTER

8.3.1 LENTIVIRUS PROMOTER VECTORS

8.3.2 LENTIVIRUS PROMOTERLESS VECTORS

8.4 LENTIVIRAL FUSION TAGS

8.5 OTHERS

9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE

9.1 OVERVIEW

9.2 PRODUCT

9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)

9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)

9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)

9.3 SERVICES

10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION

10.1 OVERVIEW

10.2 4TH GENERATION

10.3 3RD GENERATION

10.4 2ND GENERATION

10.5 1ST GENERATION

11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW

11.1 OVERVIEW

11.2 UPSTREAM PROCESSING

11.2.1 VECTOR AMPLIFICATION & EXPANSION

11.2.2 VECTOR RECOVERY/ HARVESTING

11.3 DOWNSTREAM PROCESSING

11.3.1 PURIFICATION

11.3.2 FILL-FINISH

12 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD

12.1 OVERVIEW

12.2 IN-VIVO

12.3 EX-VIVO

13 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION

13.1 OVERVIEW

13.2 CANCER

13.3 GENETIC DISORDERS

13.3.1 B-THALESSEMIA

13.3.2 X-LINKED ADRENO LEUKODYSTROPHY

13.3.3 METACHROMATIC LEUKODYSTROPHY

13.3.4 WISKOTT-ALDRICH SYNDROME

13.3.5 OTHERS

13.4 INFECTIOUS DISEASES

13.4.1 HIV

13.4.2 OTHERS

13.5 VETERINARY DISEASES

13.6 OTHERS

14 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 GENE THERAPY

14.2.1 RECOMBINANT PROTEIN EXPRESSION

14.2.2 FUNCTIONAL ASSAYS

14.2.3 IN VITRO TRANSCRIPTION

14.2.4 PROTEIN CHARACTERIZATION

14.2.5 OTHERS

14.3 VACCINOLOGY

15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER

15.1 OVERVIEW

15.2 ACADEMIC/ RESEARCH INSTITUTES

15.3 PHARMACEUTICAL COMPANIES

15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS

15.5 BIOTECHNOLOGY COMPANIES

15.6 CONTRACT RESEARCH ORGANIZATIONS

16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 AUSTRALIA

16.1.4 INDIA

16.1.5 SOUTH KOREA

16.1.6 SINGAPORE

16.1.7 MALAYSIA

16.1.8 THAILAND

16.1.9 INDONESIA

16.1.10 PHILIPPINES

16.1.11 REST OF ASIA-PACIFIC

17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT

19 COMPANY PROFILE

19.1 OXFORD BIOMEDICA

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 THERMO FISHER SCIENTIFIC INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 MERCK KGAA

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 LONZA

19.4.1 COMPANY SNAPSHOT

19.4.2 RECENT ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 CYTIVA (A SUBSIDIARY OF DANAHER)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 APPLIED BIOLOGICAL MATERIALS INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BATAVIA BIOSCIENCES B.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 BLUEBIRD BIO, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 CELL BIOLABS, INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CREATIVE BIOLABS

19.10.1 COMPANY SNAPSHOT

19.10.2 SERVICE PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 COBRA BIOLOGICS LIMITED

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 FINVECTOR OY

19.12.1 COMPANY SNAPSHOT

19.12.2 SERVICE PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

19.13.1 COMPANY SNAPSHOT

19.13.2 RECENT ANALYSIS

19.13.3 SERVICE PORTFOLIO

19.13.4 RECENT DEVELOPMENTS

19.14 GENEMEDI

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 ORIGENE TECHNOLOGIES, INC.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 SINO BIOLOGICAL, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SIRION-BIOTECH GMBH

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 SYSTEM BIOSCIENCES, LLC

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENTS

19.19 TAKARA BIO INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 RECENT ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 WAISMAN BIOMANUFACTURING

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tablas

TABLE 1 THERMO FISHER SCIENTIFIC

TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN

TABLE 3 KERAFAST

TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.

TABLE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 CHINA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 63 CHINA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 64 CHINA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 CHINA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 CHINA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 67 CHINA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 68 CHINA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 69 CHINA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 70 CHINA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 71 CHINA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 72 CHINA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 73 CHINA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 74 CHINA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 75 CHINA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 76 CHINA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 JAPAN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 78 JAPAN LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 79 JAPAN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 JAPAN PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 JAPAN LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 82 JAPAN LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 83 JAPAN UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 84 JAPAN DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 85 JAPAN LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 86 JAPAN LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 87 JAPAN GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 88 JAPAN INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 89 JAPAN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 90 JAPAN GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 91 JAPAN LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 93 AUSTRALIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 94 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 AUSTRALIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 96 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 97 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 98 AUSTRALIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 99 AUSTRALIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 100 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 101 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 102 AUSTRALIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 103 AUSTRALIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 104 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 105 AUSTRALIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 INDIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 108 INDIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 109 INDIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 INDIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 INDIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 112 INDIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 113 INDIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 114 INDIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 115 INDIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 116 INDIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 117 INDIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 118 INDIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 119 INDIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 120 INDIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 121 INDIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 123 SOUTH KOREA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 124 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 SOUTH KOREA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 127 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 128 SOUTH KOREA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 129 SOUTH KOREA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 130 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 131 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 132 SOUTH KOREA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 133 SOUTH KOREA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 134 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 135 SOUTH KOREA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 136 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 SINGAPORE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 138 SINGAPORE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 139 SINGAPORE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 SINGAPORE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 SINGAPORE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 142 SINGAPORE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 143 SINGAPORE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 144 SINGAPORE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 145 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 146 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 147 SINGAPORE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 148 SINGAPORE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 149 SINGAPORE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 150 SINGAPORE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 SINGAPORE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 MALAYSIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 153 MALAYSIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 154 MALAYSIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 MALAYSIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 MALAYSIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 157 MALAYSIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 158 MALAYSIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 159 MALAYSIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 160 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 161 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 162 MALAYSIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 163 MALAYSIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 164 MALAYSIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 165 MALAYSIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 166 MALAYSIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 167 THAILAND LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 168 THAILAND LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 169 THAILAND LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 THAILAND PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 THAILAND LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 172 THAILAND LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 173 THAILAND UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 174 THAILAND DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 175 THAILAND LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 176 THAILAND LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 177 THAILAND GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 178 THAILAND INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 179 THAILAND LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 THAILAND GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 181 THAILAND LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 182 INDONESIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 183 INDONESIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 184 INDONESIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 185 INDONESIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 186 INDONESIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 187 INDONESIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 188 INDONESIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 189 INDONESIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 190 INDONESIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 191 INDONESIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 192 INDONESIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 193 INDONESIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 194 INDONESIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 195 INDONESIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 196 INDONESIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 198 PHILIPPINES LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 199 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 PHILIPPINES PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 202 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 203 PHILIPPINES UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 204 PHILIPPINES DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 205 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 206 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 207 PHILIPPINES GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 208 PHILIPPINES INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 209 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 210 PHILIPPINES GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 211 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 212 REST OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

Lista de figuras

FIGURE 1 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION

FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

FIGURE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020

FIGURE 16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)

FIGURE 17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)

FIGURE 18 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2020

FIGURE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)

FIGURE 21 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020

FIGURE 24 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)

FIGURE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)

FIGURE 26 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020

FIGURE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)

FIGURE 29 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)

FIGURE 30 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020

FIGURE 32 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)

FIGURE 33 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)

FIGURE 34 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020

FIGURE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)

FIGURE 37 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)

FIGURE 38 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020

FIGURE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 41 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 42 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2020

FIGURE 44 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 45 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)

FIGURE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)

FIGURE 48 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)

FIGURE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)

FIGURE 50 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)

FIGURE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)

FIGURE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Asia-Pacific Lentiviral Vector Market is projected to grow at a CAGR of 16.1% during the forecast period by 2028.
The future market value of the Asia-Pacific Lentiviral Vector Market is expected to reach USD 207.37 million by 2028.
The major players in the Asia-Pacific Lentiviral Vector Market are Merck KGaA, FinVector Oy, Oxford Biomedica, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, Batavia Biosciences B.V., etc.
The countries covered in the Asia-Pacific Lentiviral Vector Market are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.